NEW YORK (GenomeWeb) – Genomic Health reported today that its fourth quarter revenues rose 6 percent year over year, with sharper growth in international sales and prostate cancer testing than in the company's core US breast cancer market.

For the three months ended Dec. 31, 2017, Genomic Health's total revenues were $87.5 million compared to $82.7 million in the same period last year, missing the consensus Wall Street estimate of $88.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.